BI 1291583
1397-0014
Phase 3 small_molecule active
Quick answer
BI 1291583 for Bronchiectasis is a Phase 3 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim
- Indication
- Bronchiectasis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active